|
시장보고서
상품코드
1983147
세팔로스포린 약물 시장 : 세대별, 유형별, 제형별, 적응증별, 유통 채널별, 지역별Cephalosporin Drugs Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, By Geography |
||||||
세팔로스포린 약물 시장은 2026년에 218억 7,000만 달러로 추정되며, 2033년까지 236억 5,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 기간에서 CAGR은 3.76%를 기록할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 218억 7,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 3.76% | 2033년 시장 규모 예측: | 236억 5,000만 달러 |
세팔로스포린 약물은 광범위한 스펙트럼의 반합성 베타락탐계 항생제의 일종으로 일반적으로 세균성 수막염, 중이염, 폐렴, 결핵, 상기도 감염, 안구 감염, 부비동염, 요로 감염, 피부 감염, 성병 등 세균성 감염의 치료에 사용됩니다. 가장 일반적으로 사용되는 세팔로스포린 약물은 세팔렉신, 세프트리악손, 세피심, 세프디닐, 세파크롤 등이 있습니다. 세팔로스포린 약물 시장은 에티오피아, 가나, 나이지리아, 세네갈 등 사하라 이남 아프리카 국가들에서 큰 잠재력을 가지고 있습니다. 이들 국가에서는 의료시설과 인프라가 미발달되어 있어 세균성 감염증의 유병률이 높기 때문입니다. 예를 들어, 세계보건기구(WHO)의 2018년 2월 보고서에 따르면, 이 질병의 부담이 가장 큰 지역은 서쪽의 세네갈에서 동쪽의 에티오피아에 이르는 사하라 이남의 아프리카 지역입니다. 이 지역에서는 여전히 연간 약 3만 건의 사례가 보고되고 있습니다.
시장 역학
전 세계 호흡기 감염증의 유병률 증가는 세팔로스포린 약물 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2017년 '호흡기질환의 세계 영향' 보고서에 따르면, 하기도 감염과 폐렴은 주요 사망 원인 중 두 가지로 연간 400만 명 이상의 사망자를 발생시키고 있습니다. 또한, 2015년에는 폐렴으로 인해 5세 미만 어린이 92,136명이 사망했으며, 이 연령대 사망자의 15%를 차지했습니다. 폐렴구균은 여전히 폐렴의 가장 빈번한 세균성 원인으로, 2015년 5세 미만 어린이 39만 3,000명이 사망했습니다.
그러나 미국 식품의약국(FDA)의 회수 증가 등의 요인이 세팔로스포린 약물 시장의 성장을 저해하고 있습니다. 예를 들어, 2019년 6월 루핀 리미티드는 세균 감염 치료에 사용되는 세프디닐(세팔로스포린) 경구 현탁액 1만 8,604병(60ml)을 미국 시장에서 회수했습니다. 또한, 2019년 1월에는 CGMP(현행 우수의약품 제조 및 품질 관리기준) 위반을 이유로 미국에서 세프디닐 경구 현탁액 28만 7,784개에 대한 리콜을 발표하였습니다.
본 조사의 주요 특징
- 이 보고서는 2018년을 기준 연도로 하여 2019년부터 2026년까지의 예측 기간 동안 세팔로스포린 약물 시장 규모에 대한 상세한 분석을 제공합니다.
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 보고서에서는 회사 개요, 재무 실적, 제품 포트폴리오, 지리적 분포, 유통 전략, 주요 개발 및 전략과 같은 매개 변수를 기반으로 세계 세팔로스포린 약물 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 정부 정책, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 제품 제조업체, 유통업체, 세팔로스포린 의약품 시장의 공급업체, 연구 및 컨설팅 회사, 신규 참가자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 세팔로스포린 약물 시장 : 세대별, 2026-2033년
제5장 세계의 세팔로스포린 약물 시장 : 유형별, 2026-2033년
제6장 세계의 세팔로스포린 약물 시장 : 제형별, 2026-2033년
제7장 세계의 세팔로스포린 약물 시장 : 적응증별, 2026-2033년
제8장 세계의 세팔로스포린 약물 시장 : 유통 채널별, 2026-2033년
제9장 세계의 세팔로스포린 약물 시장 : 지역별, 2026-2033년
제10장 경쟁 구도
제11장 애널리스트의 추천
제12장 섹션
KSM 26.04.15Cephalosporin Drugs Market is estimated to be valued at USD 21.87 Bn in 2026 and is expected to reach USD 23.65 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.76% 2025 To 2032 from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 21.87 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.76% | 2033 Value Projection: | USD 23.65 Bn |
Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization's (WHO) report of February 2018, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.
Market Dynamics
Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.
However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.
Key features of the study
- This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 - 2026, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cephalosporin drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- By Generation
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- By Type
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- By Formulation
- Oral
- Tablets
- Capsules
- Liquid
- Injection
- By Indication
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others
- Meningitis
- Acute Abdomen Infection
- Pelvic infection
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Merck & Co. Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Allergan plc.
- Abbott Laboratories
- Basilea Pharmaceutica Ltd.
- Sanofi S.A.
- Hoffmann-La Roche AG
- Lupin Limited
- Teva Pharmaceutical Industries Ltd.
- Braun Melsungen AG.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Type
- Market Snippet, By Formulation
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Cephalosporin Drugs Market, By Generation, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- First-Generation Cephalosporin
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Second-Generation Cephalosporin
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Third-Generation Cephalosporin
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Fourth-Generation Cephalosporin
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Fifth-Generation Cephalosporin
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Cephalosporin Drugs Market, By Type, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Branded Cephalosporin Drugs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Generic Cephalosporin Drugs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Cephalosporin Drugs Market, By Formulation, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Tablets
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Capsules
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Liquid
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Injection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Cephalosporin Drugs Market, By Indication, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Respiratory Tract Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Skin Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ear Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Bacterial Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Urinary Tract Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Sexually Transmitted Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Sinus Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Surgical Prophylaxis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Meningitis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Acute Abdomen Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pelvic Infection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
8. Global Cephalosporin Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
9. Global Cephalosporin Drugs Market, By Region, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- GlaxoSmithKline plc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Pfizer Inc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Allergan plc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Abbott Laboratories
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Basilea Pharmaceutica Ltd.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Sanofi S.A.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- F. Hoffmann-La Roche AG
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Lupin Limited
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- B. Braun Melsungen AG.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
11. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. Section
- References
- Research Methodology
- About Us and Sales Contact
